Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2015-2025
Biosimilar drug producers – your guide to those companies’ activities and prospects
What does the future hold for makers of biosimilar medicines? Discover those companies’ outlooks from 2015. You see results, trends, opportunities and revenue forecasting.
Visiongain’s new study analyses 25 leading developers, producers and marketers of biosimilars. That work also covers other firms, including big pharma companies entering that industry. There you assess potentials of established competitors and emerging players.
That analysis is for everyone interested in the future of biopharmaceuticals. Biosimilar drug sales expand fast, and that market holds vast potential. See now how you can benefit.
Forecasts and other data to help you stay ahead in knowledge of those biological drugs
In that updated report you find analytical profiles of the top 25 biosimilar drug companies worldwide. There you analyse products, sales results, R&D and market shares. See qualitative analyses too for those biologics, and discussions of many other relevant firms.
There gain 61 tables, 43 charts and two interviews with companies. That work lets you assess the most lucrative parts of the industry for biosimilar drugs (follow-on biologics or subsequent entry biologics). Explore the future of those recombinant therapeutic proteins.
See how you can benefit your research, analyses and decisions on those protein-based medicines. Also save time. And avoid struggles to find business information. Instead stay ahead for knowledge on the present and future of those biological drugs.
So explore changes that affect the biologics industry from 2015. And the following sections explain what you get in our investigation.
Therapy classes giving biosimilars – what’s happening there?
First our new study discusses biotechnological agents giving biosimilars. It shows that market’s advances, results and potentials.
There find prospects for developments and competition in these eight biosimilar classes:
Beijing SL Pharmaceutical
Bio Technology General Corporation
Biolab Sanus Farmacêutica
Biovel Life Sciences
Brazil’s National Economic Development Bank (BNDES)
Brazilian Ministry of Health
Brazilian Ministry of Science and Technology (MST)
Catalent Pharma Solutions
China Israel Value Capital
Chongqing Fochon Pharmaceutical Research Co.
Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris)
Committee for Medicinal Products for Human Use (CHMP)
Competitions Commission of India (CCI)
Dainippon Sumitomo Pharma
Dr. Reddy's Laboratories
Drugs Controller General of India
European Medicines Agency (EMA)
Financier of Studies and Projects (FINEP)
Food and Drug Administration (FDA)
Fujifilm Kyowa Kirin Biologics
Gan & Lee Pharmaceutical
Generex Biotechnology Corporation
Human Genome Sciences
Indian Clinical Trials Registry (CTRI)
Japan's Ministry of Health, Labour and Welfare
Johnson & Johnson
Korean Food and Drug Administration (KFDA)
Kyowa Hakko Kirin
LG Life Sciences
Marvel Life Sciences
Medice Arzneimittel Pütter GmbH & Co. KG
Meiji Seika Pharmaceuticals
Merck & Co.
MJ Bioton Life Sciences
National Autonomous University of Mexico (UNAM)
National Council for Science and Technology (CONACyT)
Oswaldo Cruz Foundation
Reliance Life Sciences
Richter-Helm BioTec GmbH & Co. KG
Shanghai Celgen Biopharmaceutical
Shanghai CP Guojian
Shanghai Fosun Pharmaceuticals
Shanghai Henlius Biotech Co.
Shanghai Lansheng Guojian Pharmaceutical Co. Ltd
Shanghai Pharmaceutical Group
Shreya Life Sciences
Sidus Pharmaceutical Group
State's Employees´ Social Security and Social Services Institute (ISSSTE)
Tat BioTech Holdings Limited
Teva Pharmaceutical Industries
US Centers for Disease Prevention and Control (CDC)
World Health Organization (WHO)
Xiamen Amoytop Biotech